Department of Gastroenterology, School of Medicine, Marmara University, Istanbul, Turkey.
Department of Internal Medicine, School of Medicine, Marmara University, Istanbul, Turkey.
Turk J Gastroenterol. 2021 Aug;32(8):685-693. doi: 10.5152/tjg.2021.20677.
A small proportion of all hepatocellular carcinomas (HCCs) arise in a non-cirrhotic liver (NCL). However, our knowledge about the HCCs developing in a NCL is scarce. This study was undertaken to investigate the characteristics and survival course of this patient group.
We retrospectively analyzed the database of patients with HCC at a tertiary center during a 10-year period (2009-2019). All demographic, clinical, laboratory, and tumoral features with survival outcomes were compared between the HCC-CL and HCC-NCL groups.
Out of 384 HCC cases, 11.2% (n = 43) had no cirrhosis. The dominant etiology in the HCC-NCL group was hepatitis B virus (n = 26, 60.5%), followed by non-alcoholic fatty liver disease (n = 10, 23.2%), and hepatitis C virus (n = 7, 16.3%). The maximum tumor diameter was approximately 2 times larger in the HCC-NCL group (HCC-NCL: 90 mm vs. HCC-CL: 46.5 mm, P < .001). The proportion of patients with vascular (HCC-NCL: 27.9% vs. HCC-CL: 8.6%, P < .001) and extrahepatic invasion (HCC-NCL: 14% vs. HCC-CL: 3%, P = .001) were prominently higher in the HCC-NCL group. Patients with HCC-NCL were less often detected in early-curable stages (BCLC 0-A) than those in the HCC-CL group (HCC-NCL: 16.3% vs. HCC-CL: 34.9%, P = .004). The overall survival was not different between the 2 groups (HCC-NCL: 19.4 ± 9.8 months vs. HCC-CL: 17.5 ± 2.3 months, P = .581).
HCC in NCL is diagnosed at more advanced tumoral stages with larger tumor size and more often with vascular and extrahepatic spread. Despite the preserved liver functions, the overall survival is not prolonged in HCCs without cirrhosis, due to the late recognition.
一小部分肝细胞癌(HCC)发生在非肝硬化肝脏(NCL)中。然而,我们对 NCL 中发生的 HCC 知之甚少。本研究旨在探讨该患者群体的特征和生存过程。
我们回顾性分析了一家三级中心在 10 年期间(2009-2019 年)的 HCC 患者数据库。比较 HCC-CL 和 HCC-NCL 两组患者的所有人口统计学、临床、实验室和肿瘤特征以及生存结果。
在 384 例 HCC 病例中,11.2%(n=43)无肝硬化。HCC-NCL 组的主要病因是乙型肝炎病毒(n=26,60.5%),其次是非酒精性脂肪性肝病(n=10,23.2%)和丙型肝炎病毒(n=7,16.3%)。HCC-NCL 组的最大肿瘤直径大约是 HCC-CL 组的两倍(HCC-NCL:90mm vs. HCC-CL:46.5mm,P<.001)。HCC-NCL 组血管侵犯(HCC-NCL:27.9% vs. HCC-CL:8.6%,P<.001)和肝外侵犯(HCC-NCL:14% vs. HCC-CL:3%,P=.001)的患者比例明显更高。与 HCC-CL 组相比,HCC-NCL 组患者早期可治愈阶段(BCLC 0-A)的检出率较低(HCC-NCL:16.3% vs. HCC-CL:34.9%,P=.004)。两组的总体生存率无差异(HCC-NCL:19.4±9.8 个月 vs. HCC-CL:17.5±2.3 个月,P=.581)。
NCL 中的 HCC 在肿瘤分期较晚时被诊断出来,肿瘤较大,且更常伴有血管和肝外扩散。尽管肝功能保持正常,但由于认识较晚,无肝硬化的 HCC 患者的总体生存率并未延长。